News

Kura Oncology Celebrates Major KOMZIFTI Sale Milestone

Kura Oncology Celebrates Major KOMZIFTI Sale Milestone

Kura Oncology Celebrates Major Milestone with KOMZIFTI™

Kura Oncology, Inc. (NASDAQ: KURA), a leader in biopharmaceuticals dedicated to developing precision medicines for cancer treatment, recently reached an important milestone in its journey. The company has successfully completed the first commercial sale of KOMZIFTI™ (ziftomenib) in the U.S. This launch marks a significant achievement, highlighting Kura’s commitment to advancing cancer therapies and improving patient outcomes.

Understanding the KOMZIFTI™ Breakthrough

KOMZIFTI™, which is a menin inhibitor, has been designed specifically for adults suffering from relapsed or refractory NPM1-mutated acute myeloid leukemia. This milestone sale activates a substantial $135 million payment from Kyowa Kirin, a collaboration partner, which Kura anticipates receiving shortly. This infusion of funds plays a pivotal role in driving further innovations and enhancements in Kura's drug development pipeline.

The Importance of Strategic Partnerships

The collaboration between Kura and Kyowa Kirin is instrumental in advancing the capabilities of both companies. By leveraging each other’s expertise, they aim to bring forth groundbreaking therapies that can substantially benefit patients. The sale of KOMZIFTI not only signifies financial success but also showcases the effectiveness of strategic partnerships in the pharmaceutical industry.

Pipeline Focus on Precision Medicine

Kura’s strong focus on precision medicine is evident in its robust pipeline of small molecule drug candidates. These candidates are specifically engineered to target critical cancer signaling pathways, addressing urgent needs in hematologic malignancies and solid tumors. KOMZIFTI exemplifies Kura's innovative approach to cancer treatment, aiming to address some of the most pressing challenges faced by patients today.

The Future of Kura Oncology

Looking ahead, Kura Oncology is poised to make significant strides in the oncology field. The company’s dedication to research and development is unwavering, with ongoing efforts to discover and develop therapies that are not only effective but also meet the unique needs of patients. The recent commercial success of KOMZIFTI serves as a springboard for future advancements and reinforces the company’s mission of transforming cancer treatment.

Conclusion and Company Commitment

The completion of the KOMZIFTI sale signifies a monumental step for Kura Oncology, reflecting its successful strategic maneuvering and the potential to revolutionize cancer care. With a commitment to delivering innovative therapies that meet the needs of patients, Kura is leading the way toward a brighter future in oncology. The partnership with Kyowa Kirin will continue to strengthen Kura's position and contribute to a comprehensive approach to cancer treatment.

Frequently Asked Questions

What is KOMZIFTI™ used for?

KOMZIFTI™ is an oral menin inhibitor indicated for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.

How much is the milestone payment from Kyowa Kirin?

The milestone payment triggered by the first U.S. sale of KOMZIFTI™ is $135 million.

When was KOMZIFTI™ approved by the FDA?

KOMZIFTI™ received FDA approval on November 13, 2025.

What role does Kyowa Kirin play in Kura Oncology?

Kyowa Kirin collaborates with Kura Oncology through a license agreement, supporting the development and commercialization of KOMZIFTI™.

Who can I contact for more information about Kura Oncology?

For additional inquiries, reach out to Greg Mann at Kura Oncology via email at gmann@kuraoncology.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Innovative CORDStrom™ Platform by INmune Bio

Updated Category News Views 200

Introduction to CORDStrom™ and Its Significance INmune Bio, Inc. (NASDAQ: INMB), a pioneer in the field of inflammation and immunology therapies, has recently sparked significant interest in the medical community. Their intriguing CORDStrom™ platform signifies a promising advance in mesenchymal stromal cell (MSC) therapies, aiming to address various health conditions...

Continue Reading
Brooklyn Law School Enhances Scholarship Support for Veterans

Updated Category News Views 156

Brooklyn Law School Expands Support for Veteran Students Brooklyn Law School has taken significant steps to demonstrate its commitment to veterans by increasing scholarship support, ensuring they receive the assistance they need to excel in their legal education. This initiative reflects a profound recognition of the sacrifices made by our armed forces members and aims to...

Continue Reading
Unlocking Creativity with the New vivo X200 FE Smartphone

Updated Category News Views 441

Introducing the vivo X200 FE: Ideal for the Innovative Generation Vivo proudly announces the launch of the X200 FE, a cutting-edge smartphone designed with the vibrant essence of the new generation in mind. This model combines playful aesthetics with dependable functionality, delivering an exceptional user experience. With its striking color-blocking design and advanced...

Continue Reading
Exploring Market Sentiment Towards Westinghouse Air Brake Tech

Updated Category News Views 201

Current Sentiment Around Westinghouse Air Brake Technologies Corp Westinghouse Air Brake Technologies Corp (NYSE: WAB) is a prominent player in the transportation industry, particularly known for its innovation in braking systems and other technology. Recently, it has come to light that the short interest as a percentage of its float has decreased significantly, by...

Continue Reading
Asante Gold Highlights Shareholder Meeting Information and Voting

Updated Category News Views 165

Key Information about Asante Gold's Upcoming Shareholder Meeting Your participation is crucial, regardless of how many shares you own in Asante Gold. The Company’s Board of Directors strongly advises all shareholders to vote for all resolutions presented. Proxy Materials Available Online Asante Gold Corporation (TSXV: ASE | GSE: ASG | OTCQX: ASGOF) has announced that...

Continue Reading